Anakinra was not associated with lower mortality in hospitalised COVID‐19 patients: A systematic review and meta‐analysis of randomized controlled trials

Abstract

The Coronavirus disease‐2019 (COVID‐19) pandemic continues, and the death toll continues to surge. This meta‐analysis aimed to determine the efficacy of anakinra on mortality in patients with COVID‐19. A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials on treatment of COVID‐19 with anakinra, compared with placebo or blank, were reviewed. Studies were pooled to risk ratios (RRs), with 95% confidence intervals (CIs). Five Randomized controlled trials (enrolling 1859 participants) met the inclusion criteria. There was no statistically significant difference in 14‐day mortality (RR 0.78, 95% CI 0.43–1.39; P = 0.40), 28‐day mortality (RR 1.06, 95% CI 0.89–1.26; P = 0.51), and 90‐day mortality (RR 1.01, 95% CI 0.73–1.39; P = 0.97) between the two groups. Sensitivity analyses further confirmed these results. Anakinra was not associated with reduced mortality in hospitalised patients with COVID‐19. Anakinra probably should not be used routinely in COVID‐19 patients.

Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial

“… 1 , 2 , 3 Treatment of hospitalized patients with severe COVID-19 symptoms generally includes supportive oxygenation, corticosteroids administration when viral replication has declined, 4 , 5 remdesivir and immunomodulators. However, antibodies targeting inflammatory cytokines show heterogeneous results 6 and antivirals are of limited efficacy in patients hospitalized with severe COVID-19. 7 , 8 Thus, new therapeutic options are still required to limit respiratory failure and mortality in this indication.…”

Long‐term safety of macitentan in patients with pulmonary hypertension: A meta‐analysis of randomised controlled trials

“…And a p value <0.05 was taken to indicate statistical significance. The P value of Begg's rank correlation test [18][19][20] (STATA version 12.0) was used to assess the presence of publication bias in included articles for each outcome.…”

Is immunosuppressive therapy an effective treatment for COVID-19? – literature review

“…To sugerowało, że anakinra jest potencjalnie silnym kandydatem na środek przeciwzapalny w celu zmniejszenia śmiertelności u pacjentów z COVID-19, szczególnie u pacjentów z podwyższonymi biomarkerami stanu zapalnego. [33][34][35].…”